Odyssey Therapeutics (NASDAQ:ODTX) Price Target Raised to $29.00 at JPMorgan Chase & Co.

Odyssey Therapeutics (NASDAQ:ODTX) had its target price boosted by JPMorgan Chase & Co. from $26.00 to $29.00 in a report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts have also recently issued reports about the stock. TD Cowen initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set a “buy” rating on the stock. Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating on the stock. Wedbush started coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price target for the company. Finally, Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a report on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

Odyssey Therapeutics Trading Down 1.8%

Odyssey Therapeutics stock opened at $21.17 on Friday. Odyssey Therapeutics has a 12 month low of $15.10 and a 12 month high of $22.26. The stock has a 50-day moving average price of $17.87.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, equities analysts forecast that Odyssey Therapeutics will post -4.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Tpg Gp A, Llc bought 1,388,889 shares of Odyssey Therapeutics stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $18.00 per share, with a total value of $25,000,002.00. Following the completion of the transaction, the insider owned 3,690,146 shares in the company, valued at approximately $66,422,628. This trade represents a 60.35% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Shelley Chu bought 11,111 shares of Odyssey Therapeutics stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the completion of the transaction, the director owned 11,111 shares of the company’s stock, valued at approximately $199,998. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 3,066,666 shares of company stock worth $55,199,988 in the last 90 days.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.